مقايسة مستويات الأدديبونكتين عند مرضى الفشل القلبي، و ارتباطها بوخامة المرض

Abstract EN

Adiponectin, an adipocyte-derived hormone, is expressed in adipose tissue and directly sensitizes the body to insulin.

It enhances fatty acid oxidation in skeletal, cardiac muscle and in the liver, thus reducing triglyceride content in these tissues.

It stimulates glucose uptake by skeletal and cardiac muscle.

Hypoadiponectinemia has been identified as an independent risk factor for type 2 diabetes, coronary artery disease (CAD), and hypertension.

experimental studies show that adiponectin plays a protective role in the development of insulin resistance, atherosclerosis, and inflammation.

More recent findings have shown that adiponectin directly affects signaling in myocardial cells and exerts beneficial actions on the heart after ischemia–reperfusion injury.

Whereas the relationship between low adiponectin levels and increased CAD or myocardial infarction risk has been established, the role of plasma adiponectin in congestive heart failure (CHF) appears to be more complex.

This study focuses on Association of hyperadiponectinemia with severity of heart failure.

Objectives: To determine serum adiponectin levels in patients with congestive heart failure (CHF).

Methods and results: our study group comprised 110 patients with CHF who were divided into 4 subgroups according to New York Heart Association (NYHA) functional class, and 27 control subjects.

Serum levels of adiponectin were determined.

Serum adiponectin levels were significantly increased according to the NYHA class in the patients with CHF; control: 5.6±2.29 μg/ml, NYHA II: 9.14±7.18 μg/ml, NYHA III: 13.68±12.06 μg/ml.

NYHA IV: 22.34±16.08 μg/ml (p<0.05).

Conclusion: serum adiponectin increased according to the severity of CHF.

These results indicate that release of adiponectin is involved in the pathogenesis of CHF